Heidelberg Pharma AG's First Quarter Financial Report for 2025

Heidelberg Pharma AG released its interim statement for the first three months of 2025, highlighting progress in clinical trials and financial planning. The company's lead candidate, HDP-101, showed safety and promising results in phase I/IIa trials for multiple myeloma, with cohort 8 soon to commence. Additionally, the HDP-102 program targeting non-Hodgkin lymphoma has initiated clinical testing.

Financially, Heidelberg Pharma secured an amendment to its agreement with HealthCare Royalty, resulting in a USD 20 million payment and extending their cash reach into 2027. The company reported sales and revenue totaling EUR 2.9 million, up from EUR 1.9 million the previous year. However, the net loss increased to EUR 5.9 million, compared to EUR 4.5 million in the same period last year.

Looking ahead, the company anticipates sales between EUR 9-11 million and an operating result ranging from EUR -30 to -35 million for 2025, propelled by expected financial inflows and continuing advancements in its ADC programs.